Immune-based therapies for treatment of HIV infection

被引:6
|
作者
Piscitelli, SC [1 ]
Minor, JR [1 ]
Saville, MW [1 ]
Davey, RT [1 ]
机构
[1] NIAID, LAB IMMUMOREGULAT, BETHESDA, MD 20892 USA
关键词
D O I
10.1177/106002809603000111
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the in vitro, animal, and clinical data on immune-based therapies for treatment of HIV infection. DATA SOURCES: An extensive MEDLINE search was performed for interleukins, interferons, immunotoxins, tumor necrosis factor (TNF)-directed agents, vaccines, and gene therapy. STUDY SELECTION: In vitro experiments with immune-based agents in cell lines infected with HIV were included. In addition, all human studies and case reports that used these agents in patients infected with HIV were selected. Additional literature included abstracts from international meetings on HIV and AIDS. DATA EXTRACTION: Data regarding activity, efficacy, and toxicity a were extracted from in vitro and in vivo studies. When conflicting data were observed, both viewpoints were stated to give an unbiased analysis. Because HIV research involves multiple social, ethical, and scientific issues, perspectives on these problems were addressed, where appropriate. DATA SYNTHESIS: Current antiretroviral therapy is limited to short-term responses and has minimal effect on overall survival. Because the human immune response to HIV infection is effective at keeping the virus suppressed for a number of years, a focus of HIV research has been to examine immune-based therapies for treatment of HIV infection that attempt to augment, enhance, or boost the patient's immune system. Interleukins, interferons, immunotoxins, TNF-directed therapies, vaccines, and gene therapy have been studied in patients infected with HN. Properties shared among these therapeutic modalities include adverse effect profiles, response rates dependent on baseline immunocompetence, the potential to activate viral replication, the need for supportive care, and sensitive laboratory tests required for monitoring. CONCLUSIONS: Immune-based agents represent a new approach to the treatment of HIV infection. Whereas antiretrovirals only inhibit viral replication, these agents are designed to enhance the immune system of the patient. Future attempts to manage HIV infection may combine standard nucleoside analogs with immune-based therapies.
引用
收藏
页码:62 / 76
页数:15
相关论文
共 50 条
  • [1] Immune-based therapies and HIV infection
    Weiss, L
    [J]. ANNALES DE MEDECINE INTERNE, 2002, 153 (04): : 227 - 236
  • [2] Rationale for immune-based therapies for HIV-1 infection
    Valdez, H
    Al-Harthi, L
    Landay, A
    Lederman, MM
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (03): : 197 - 206
  • [3] STATUS OF IMMUNE-BASED THERAPIES IN HIV-INFECTION AND AIDS
    FAHEY, JL
    SCHOOLEY, R
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1992, 88 (01): : 1 - 5
  • [4] Ongoing trials of immune-based therapies for HIV infection in adults
    Ross, RW
    Wright, ME
    Tavel, JA
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) : 413 - 424
  • [5] Immune-based therapies for cytomegalovirus infection
    Razonable, Raymund R.
    [J]. IMMUNOTHERAPY, 2010, 2 (01) : 117 - 130
  • [6] Immune-based therapy for HIV infection
    Benson, EM
    French, MAH
    Schooley, RT
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1996, 164 (05) : 297 - 300
  • [7] Treatment duration with immune-based therapies in Cancer: an enigma
    Bantia, Shanta
    Choradia, Nirmal
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [8] Immune-based therapies: an adjunct to antiretroviral treatment.
    Jacobson J.M.
    [J]. Current HIV/AIDS Reports, 2005, 2 (2) : 90 - 97
  • [9] Immune-based therapy for HIV infection: Are acute and chronic HIV infection different diseases?
    Hunt, Peter W.
    Deeks, Steven G.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12): : 1632 - 1634
  • [10] ANTIRETROVIRAL AND IMMUNE-BASED THERAPIES - UPDATE
    YENI, P
    SCHOOLEY, R
    HAMMER, S
    [J]. AIDS, 1993, 7 : S173 - S184